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With the onset of prevention trials for individuals at high risk for Alzheimer disease, there is
increasing need for accurate risk prediction to inform study design and enrollment, but avail-
able risk estimates are limited. We developed risk estimates for the incidence of mild cogni-
tive impairment (MCI) or dementia among cognitively unimpaired individuals by APOE-e4
dose for the genetic disclosure process of the Alzheimer’s Prevention Initiative Generation
Study, a prevention trial in cognitively unimpaired APOE-e4/e4 homozygote individuals.
Methods and findings
We included cognitively unimpaired individuals aged 60–75 y, consistent with Generation
Study eligibility criteria, from the National Alzheimer’s Coordinating Center (NACC) (n =
5,073, 158 APOE-e4/e4), the Rotterdam Study (n = 6,399, 156 APOE-e4/e4), the Framing-
ham Heart Study (n = 4,078, 67 APOE-e4/e4), and the Sacramento Area Latino Study on
Aging (SALSA) (n = 1,294, 11 APOE-e4/e4). We computed stratified cumulative incidence
curves by age (60–64, 65–69, 70–75 y) and APOE-e4 dose, adjusting for the competing risk
of mortality, and determined risk of MCI and/or dementia by genotype and baseline age. We
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also used subdistribution hazard regression to model relative hazard based on age, APOE
genotype, sex, education, family history of dementia, vascular risk, subjective memory con-
cerns, and baseline cognitive performance. The four cohorts varied considerably in age, educa-
tion, ethnicity/race, and APOE-e4 allele frequency. Overall, cumulative incidence was uniformly
higher in NACC than in the population-based cohorts. Among APOE-e4/e4 individuals, 5-y
cumulative incidence was as follows: in the 60–64-y age stratum, it ranged from 0% to 5.88% in
the three population-based cohorts versus 23.06% in NACC; in the 65–69-y age stratum, from
9.42% to 10.39% versus 34.62%; and in the 70–75-y age stratum, from 18.64% to 33.33% ver-
sus 38.34%. Five-year incidence of dementia was negligible except for APOE-e4/e4 individuals
and those over 70 y. Lifetime incidence (to age 80–85 y) of MCI or dementia for the APOE-e4/
e4 individuals in the long-term Framingham and Rotterdam cohorts was 34.69%–38.45% at
age 60–64 y, 30.76%–40.26% at 65–69 y, and 33.3%–35.17% at 70–75 y. Confidence limits
for these estimates are often wide, particularly for APOE-e4/e4 individuals and for the dementia
outcome at 5 y. In regression models, APOE-e4 dose and age both consistently increased risk,
as did lower education, subjective memory concerns, poorer baseline cognitive performance,
and family history of dementia. We discuss several limitations of the study, including the small
numbers of APOE-e4/e4 individuals, missing data and differential dropout, limited ethnic and
racial diversity, and differences in definitions of exposure and outcome variables.
Conclusions
Estimates of the absolute risk of MCI or dementia, particularly over short time intervals, are
sensitive to sampling and a variety of methodological factors. Nonetheless, such estimates
were fairly consistent across the population-based cohorts, and lower than those from a
convenience cohort and those estimated in prior studies—with implications for informed
consent and design for clinical trials targeting high-risk individuals.
Author summary
Why was this study done?
• Having one copy of the e4 variant of the APOE gene (APOE-e4) is associated with
increased risk and earlier onset age of Alzheimer disease dementia, and the 1%–2% of
the population who carry two copies of this variant (APOE-e4/e4) are at especially
increased risk.
• For this reason, individuals with APOE-e4/e4 are being targeted for special preven-
tion strategies.
• Accurate risk estimates allow potential participants in prevention trials to compare
the risk of developing Alzheimer disease dementia to any risk associated with the
preventive intervention itself.
• Such estimates also help those planning trials decide how many participants they need.
• The risk that an individual with APOE-e4/e4 will develop Alzheimer disease demen-
tia has been reported to be as high as 50%–67%, but these estimates come from statis-
tical modeling, not direct observation.
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• Our study was designed to develop risk estimates for potential participants in the
Generation Study, a prevention trial in individuals with APOE-e4/e4, as well as esti-
mates for those with one or no copies of APOE-e4. The non-APOE-e4/e4 individuals
are not eligible for the Generation Study, but participate in genetic counseling as
part of the recruiting process, and might be eligible for future trials.
What did the researchers do and find?
• We examined data from 16,844 individuals, 292 with APOE-e4/e4, from four different
samples of cognitively normal older individuals aged 60–75 years (consistent with the
eligibility criteria for the Generation Study). These individuals have been followed for
an average of 4 to 18 years and assessed for the development of dementia or a less seri-
ous condition called mild cognitive impairment that sometimes leads to dementia.
• We divided each sample into six groups based on the number of copies of APOE-e4
(none, one, and two, i.e., APOE-e4/e4) and age (60–64, 65–69, and 70–75 years), and
developed estimates of the risk of developing mild cognitive impairment or dementia
in each group during the five years planned for the trial as well as “lifetime” risk
through age 80–85 years.
• Five-year risk was highly variable across the four samples within each group; for
APOE-e4/e4 individuals, it ranged from 0% to 23% in those entering the study at age
60–64 years, 9% to 35% in those entering at 65–69 years, and 19% to 38% in those
entering at 70–75 years.
• Lifetime risk was more consistent across the two samples in which it could be esti-
mated, and did not vary as much with age, ranging from 31% to 40% for those with
APOE-e4/e4.
• We developed statistical models to understand the differences across the four samples.
These analyses showed that, beyond age and APOE-e4, the following variables were asso-
ciated with increased risk: less education, memory concerns or poorer cognitive screen-
ing test scores at the beginning of follow-up, and having a family history of dementia.
• Differences in these characteristics, differences in methods of recruiting and evaluat-
ing participants, and statistical fluctuation probably account for a large share of the
variety in risk estimates across the samples.
What do these findings mean?
• The risk of dementia in those with APOE-e4/e4 is somewhat lower than previously
estimated.
• Short-term risk is more subject to variability due to details of how a particular study
is conducted than longer-term risk.
• This information is valuable to those considering joining a prevention trial, as well as
those designing such trials.
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Introduction
At present, 48 million people worldwide have dementia, and this number is projected to
increase to 131 million by 2050 [1]. Consequently, prevention of Alzheimer disease, the most
common cause of dementia, has become a major research focus, with several prevention
trials now underway [2–7]. The feasibility of these trials will in part depend on the ability to
recruit individuals at risk of developing disease during the trial period. One strategy to achieve
this focuses on individuals at high genetic risk. The Alzheimer’s Prevention Initiative [8] is
embarking on two clinical trials targeting cognitively unimpaired individuals at highest genetic
risk for Alzheimer disease, one trial in an extended early-onset Columbian kindred carrying a
fully penetrant presenilin 1 mutation, and the Generation Study (NCT02565511), a trial in
individuals aged 60–75 y who carry two copies of the Alzheimer disease risk allele apolipopro-
tein E epsilon 4 (APOE-e4). The Generation Study is a double-blind, randomized, placebo-
controlled clinical trial of two different anti-amyloid agents in approximately 1,300 partici-
pants. Recruitment is through several sources, notably in the United States through the Gene-
Match [9] Alzheimer disease prevention registry (NCT02564692). High-volume recruitment
efforts are required because the APOE-e4/e4 genotype occurs in approximately 1%–2% of the
general population, so thousands of individuals must be screened to identify eligible partici-
pants. An assessment of absolute risk among trial-eligible individuals in a meaningful time
frame is essential for the informed consent process in the trial, as well as trial design. However,
although numerous studies [10–14] document that APOE-e4 increases the relative risk of Alz-
heimer disease (compared to no copies of APOE-e4, there is a 2- to 4-fold increase in risk for
one copy of APOE-e4, and an 8-to 15-fold increase for two copies), its effect on absolute risk is
less clear.
When this study was begun, available estimates of absolute risk of dementia for APOE-e4
carriers were largely based on models developed from relative risks observed in one population
and incidence data from another, often from case–control samples. The Risk Evaluation and
Education for Alzheimer’s Disease (REVEAL) study [15,16] developed risk estimates [17]
based on observed absolute risks in first-degree relatives versus spouses in a family sample
[18], and then applied relative risks by sex, age, and genotype from a large meta-analysis [14].
A more recent effort [19], also reported on the 23andMe website [20], applied relative risks
from a recent European genome-wide association study (GWAS) sample [21] to incidence
estimates from the Rochester [22] and Personnes Age´es QUID (PAQUID) [23] cohorts to
compute lifetime risks by APOE genotype. Since that time, estimates from a single convenience
cohort have been published, also with high incidence rates [24].
Because the available estimates of the APOE-associated incidence of mild cognitive
impairment (MCI) or dementia are primarily based on models of disease onset rather than
prospective observations, and because APOE also affects longevity and risk for diseases other
than dementia, we developed new estimates in population-based cohorts to better inform both
trial designers and potential participants. For potential Generation Study participants, the out-
reach and recruitment protocol for those who do not know their APOE genotype includes
institutional review board (IRB)–approved processes for obtaining their genotype and inviting
them to a trial site for an initial disclosure visit. To ensure an appropriate disclosure setting
during trial enrollment, some prospective participants without the APOE-e4/e4 genotype are
also invited for this initial genetic disclosure visit. Our aims were to use prospective data to
determine 5-y and lifetime risk of MCI or dementia by age and APOE-e4 dose among those as
similar as possible to eligible trial participants (age 60–75 y, normal cognition) and to identify
sources of heterogeneity that may account for variation in risk across populations.
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Methods
Ethics statement
The Rotterdam Study was approved by a medical ethics committee according to the Popula-
tion Study Act Rotterdam Study, executed by the Ministry of Health, Welfare and Sport of the
Netherlands; written informed consent was obtained from all participants. The Framingham
Heart Study was reviewed by the IRB at Boston University Medical Center, and all participants
gave written informed consent. The Sacramento Area Latino Study on Aging (SALSA) was
reviewed by the IRBs at the University of Michigan and at the University of California at San
Francisco and at Davis, and all participants gave written informed consent. Collection of data
for the National Alzheimer’s Coordinating Center (NACC) Uniform Data Set cohort was
reviewed by the appropriate local IRB at each participating Alzheimer’s Disease Center, and all
participants gave written informed consent; research using the NACC database was approved
by the University of Washington IRB. The IRBs at Partners HealthCare in Boston and the Uni-
versity of Massachusetts Amherst provided additional approvals for the secondary data analy-
sis reported here. This study is reported as per STROBE reporting guidelines (S1 Checklist).
Cohort selection
We sought available data from longitudinal population-based cohorts based on the following
attributes: recruitment and an initial cognitive evaluation at or before age 60 y (because the
Generation Study is recruiting individuals aged 60–75 y, and we wanted our risk assessments
to be maximally relevant to those entering the trial), ongoing surveillance for assessment of
MCI and dementia, and available APOE genotypes. Many aging-focused cohorts (e.g., the Reli-
gious Orders Study [25] and the Cache County Study [26]) did not meet these criteria because
of initial ascertainment at older ages. We also sought as broad ethnic representation as possi-
ble: we were able to include one Hispanic population with limited sample size, but no African-
American cohort was available with the requisite data.
Three population-based cohorts were analyzed: the Framingham Heart Study [27], the Rot-
terdam Study [28], and the SALSA Study [29,30]. For comparison, we also included the NACC
Uniform Data Set longitudinal convenience cohort [31] (from the multi-site Alzheimer’s Dis-
ease Center Program funded by the US National Institute on Aging) because we believed that
NACC participants might resemble those volunteering for the Generation Study in terms of
key demographic variables and level of research interest.
Sample selection for the present analyses
Within each cohort, we selected participants with known APOE genotype who were cogni-
tively unimpaired at the time of their first visit within the 60–75-y age window, and included
all available subsequent visit information until diagnosis of MCI or dementia. For the two lon-
ger-term studies, the Framingham Heart Study and the Rotterdam Study, individuals could
contribute to multiple age strata for the stratified analyses, but they were included only once in
our regression analyses (see “Statistical analysis” below). APOE genotype was measured in
94.1% (Rotterdam Study), 68.5% (Framingham Heart Study), 76.1% (NACC), and 92.0%
(SALSA) of otherwise eligible (i.e., cognitively normal in the age window of 60–75 y) cohort
participants, and only these individuals were included in the current study. On average, indi-
viduals without APOE genotype available were slightly older, except in the Framingham Heart
Study, where they were slightly younger; in all cases the mean difference between those with
and without APOE available was less than 1 y. Those without APOE genotype were more likely
to be female in the NACC and Rotterdam cohorts, and more likely to be male in the SALSA
APOE and risk of mild cognitive impairment or dementia for prevention trials
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and Framingham cohorts, but these differences were also small—within 1%–2%, except for the
Rotterdam cohort, where females were 66.1% of those without genotype and 54.8% of those
with genotype.
Ascertainment and assessment methods for each cohort
The original Framingham Heart Study cohort was recruited in 1948–1953 based on residence
in Framingham, Massachusetts, for a longitudinal study of cardiovascular disease (mean age at
enrollment 45 y). A cohort of offspring of the original participants and their spouses was estab-
lished in 1971–1975 (mean age at enrollment 37 y). Details of study procedures have been pub-
lished elsewhere [27]. Cognitive status has been monitored in the original cohort since 1975,
when a comprehensive neuropsychological battery was administered, followed by neurological
assessment of participants with lower cognitive test scores [32]. Since 1981, this cohort has
been assessed at each examination with a Mini-Mental State Examination (MMSE), where
participants were flagged for further cognitive screening if they scored below predefined cut-
offs based on education and prior performance. The offspring cohort has undergone similar
monitoring with serial MMSEs since 1991. Participants identified as having possible cognitive
impairment based on these screening assessments (or in reports of cognitive concerns by
the participant, family, treating physician, or Framingham ancillary study investigators, or
through review of outside medical records) are invited to undergo additional annual neurolog-
ical and neuropsychological examinations. A dementia review panel including a neurologist
and a neuropsychologist reviews each case of possible cognitive decline and dementia and cat-
egorizes participants based on the best available information (from serial neurological and
neuropsychological assessments, telephone interviews with caregivers, medical records, neuro-
imaging, and, when available, autopsy data) and assigns a diagnosis and onset date for demen-
tia according to DSM-IV criteria and for MCI based on Petersen et al. [33] criteria. Diagnoses
made prior to 2001 have been re-reviewed to update diagnostic criteria. Participants who
entered the sample for the present analyses at a visit prior to MMSE administration but who
were cognitively unimpaired at subsequent study visits had this designation extended back to
their earlier visits. For our regression analyses, these individuals were included with the base-
line visit as the first visit with MMSE administration within our age window (60–75 y).
For the Rotterdam Study, individuals over 55 y in 1990 residing in a specific district of the
City of Rotterdam, the Netherlands, were invited to participate, with additional waves invited
in 2000 (age >55 y) and 2005 (age >45 y). Details of study procedures have previously been
published [28]. In brief, all participants were interviewed at home and examined at the study
center every 4 to 5 y. Participants were routinely screened for dementia at the initial visit and
follow-up examinations using a three-step protocol. Screening was done using the MMSE
and the Geriatric Mental Schedule (GMS) organic level [2]. Those with MMSE < 26 or GMS
organic level> 0 subsequently underwent an examination and informant interview using the
Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) [34]. Additionally,
the total cohort was continuously monitored for dementia through computerized linkage
between the study database and digitized medical records. The current sample included all
participants with MMSE > 26 at the time of their first visit within the age window of interest
(60–75 y). Formal assessment of MCI did not begin until 2005 in the Rotterdam Study. For
the present analyses, we therefore developed a pragmatic diagnosis of MCI during follow-up,
requiring a MMSE score < 26 or a drop of at least three points from the baseline visit in the
60–75-y age window, plus answering yes to a question about memory concerns.
For SALSA, participants over 60 y were sampled from six counties including census tracts
with at least 5% Hispanic population in the Sacramento Valley of California in 1998–1999 and
APOE and risk of mild cognitive impairment or dementia for prevention trials
PLOS Medicine | DOI:10.1371/journal.pmed.1002254 March 21, 2017 6 / 27
were followed approximately every 12–15 mo until 2008. Detailed methods are described else-
where [29,35]. In brief, dementia assessment included screening with both the Modified Mini-
Mental State Examination (3MS) [36] and a word list learning task from a standard battery
[30]. Those scoring below the 20th percentile (using age-, education-, sex-, and language-
adjusted norms) on either test (or for follow-up visits, dropping three points in word list learn-
ing) were further evaluated using the Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE) [37,38] and, if this gave additional support for decline, were evaluated by a
neurologist and categorized as cognitively unimpaired, memory-impaired (based on testing
alone, without IQCODE corroboration), cognitively impaired not demented (CIND) [39], or
having dementia. Given the requirement for both a cognitive testing abnormality and confir-
mation from an informant, CIND was treated as equivalent to MCI [35].
Participants in the NACC cohort were volunteers ascertained from various sources at 34
Alzheimer’s Disease Centers in the United States. We used the March 2016 data freeze for the
present analyses, so these data reflect study visits between September 2005 and March 2016.
The participants were evaluated according to the Uniform Data Set protocol [40], with each
participant and a collateral informant interviewed by the study clinician to rate the Clinical
Dementia Rating (CDR) [41] and with the administration of a battery of neuropsychological
tests [42]. A diagnosis was made at each visit by the study clinician following standard criteria
[40], but there were no study-wide standardized cutoffs on the CDR, MMSE, or other neuro-
psychological tests. Follow-up visits were conducted approximately annually.
Definition of predictor variables
Education was reported in years for the SALSA and NACC cohorts and in categories of less
than high school, high school, some college, or college graduation for the Rotterdam and Fra-
mingham cohorts. Education data for the SALSA and NACC cohorts were translated into
these categories as follows: <12 y, less than high school; 12 y, high school; 13–15 y, some col-
lege; and16 y, college graduation.
To assess cognitive performance across cohorts, we used the cognitive screening test avail-
able for each site (MMSE for the Rotterdam Study, the Framingham Heart Study, and NACC,
and 3MS for SALSA). To enable comparisons of relative performance within each cohort, we
standardized based on the test score at the baseline visit (in the age 60–75-y age window)
within each cohort, centering the raw scores around their sample mean and then dividing the
centered scores by their standard deviation.
Memory concerns at NACC were based on a global clinician-rated variable asking whether
the participant believed that he or she had a problem with memory. Memory concerns in the
Rotterdam Study were based on three questionnaire items asking (1) whether the participant
was worried about his or her memory, (2) whether the participant ever lost track of what he or
she was doing in the midst of an activity, and (3) whether the participant experienced word-
finding difficulties. A positive answer to any of these questions qualified as memory concerns.
Family history of dementia was defined as having at least one parent with dementia for the
Rotterdam Study, and at least one first-degree relative with dementia for NACC.
For all cohorts, vascular risk was defined as follows. We obtained the sum of major vascular
risk factors measured in each cohort: coronary artery disease or angina or stroke, hyperten-
sion, high cholesterol, diabetes, atrial fibrillation, and current smoking. After reviewing the
distribution of the count of these risk factors (range 0–6), we categorized the participants as
high risk (3–6 risk factors), moderate risk (1–2 risk factors), and low risk (0 risk factors) to pro-
vide a reasonable distribution across the three levels. We considered using the Framingham
Stroke Risk Profile [43] or similar cardiovascular risk scores [44,45]. However, these were
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designed to predict risk within a specified time frame and thus had substantial age compo-
nents, which complicated analyses in our regression models that already included age.
Statistical analysis
We performed all analyses first for MCI or dementia (“MCI/dementia”), then for dementia
alone. For the purposes of this trial, the MCI/dementia outcome was critically relevant, in that
incident dementia was unlikely during the trial period, while there was tangible risk for MCI.
Analyses for dementia only were performed as well because dementia is a more robust out-
come than MCI.
We estimated 5-y and “lifetime” (i.e., to age 80–85 y) cumulative incidence by APOE-e4
dose and 5-y baseline age stratum (age 60–64, 65–69, 70–75 y). We chose three age strata as a
tradeoff between addressing the steeply changing risk with age and not overly subdividing the
limited numbers of APOE-e4/e4 homozygote individuals, which left the number of APOE-e4/
e4 individuals per age stratum too small for stable estimates in the SALSA cohort. These age
strata were determined specifically as follows, based on the date of the baseline visit (within the
60–75-y age window): 60–64 y, 60 age< 65; 65–69 y, 65 age< 70; and 70–75, 70 age
75. We considered further stratification on sex, but the sample size did not support such
stratification.
For the stratified analyses of the two longer-term studies, the Framingham Heart Study and
the Rotterdam Study, individuals could contribute to multiple baseline age strata; we used the
first visit within each age window as the baseline in these analyses. Lifetime estimates were
computed as 20-y cumulative incidence for the age 60–64-y stratum, as 15-y for the 65–69-y
stratum, and as 10-y for the 70–75-y stratum; these estimates were computed only for the two
longer-term cohorts to minimize extrapolation.
Stratified cumulative incidence curves by age stratum and APOE-e4 dose were estimated,
adjusting for loss to follow-up other than death and for the competing risk of mortality [46];
loss to follow-up other than death is treated as censored. In the presence of competing risks,
the naïve Kaplan–Meier estimator, which treats failure from competing causes as censored
observations, overestimates the cumulative incidence of the event of interest [47]. We used the
“cmprsk” package in R software [48] to estimate the cumulative incidence for each age stratum
by APOE-e4 dose stratum. Following the suggestion of Lin [49], we used the transformation
log[−log(1 − x)] to construct the confidence interval for cumulative incidence. The transfor-
mation not only ensures that the boundaries of cumulative incidence are contained in [0,1],
but also improves the coverage accuracy [49].
We used the same competing risks analytic framework to assess the effects of age and
APOE-e4 dose plus additional covariates on the cumulative incidence of MCI/dementia and of
dementia alone in order to inform personalized risk assessment and to understand differences
across the cohorts. We used subdistribution hazard regression models [50] because they
directly link the regression coefficients with the cumulative incidence function (in contrast to
cause-specific hazards regression [51], where the direct link cannot be made [52]; in prelimi-
nary analyses we also fit these models, and results were very similar). These analyses were also
performed using the “cmprsk” package in R software [48].
For each cohort and for each outcome, we first fit univariable models for baseline age, sex,
APOE-e4 dose, education, standardized cognitive screening test score, subjective memory con-
cerns, family history of dementia, and vascular risk score. Then, we ran simple multivariable
models for each outcome including only APOE-e4 dose and demographic factors (age, sex,
and education). Last, we ran larger multivariable models also including standardized cognitive
screening score plus subjective memory concerns and family history of dementia if available
APOE and risk of mild cognitive impairment or dementia for prevention trials
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for the cohort. The vascular risk score was not included in the full model because findings
were inconsistent and primarily null in the univariable models, whether we used our low/mod-
erate/high vascular risk levels described above or the Framingham Stroke Risk Profile.
Missing data on covariates was generally minimal, <2% for all covariates in all cohorts
except family history in the Rotterdam Study (11.5%), vascular risk in SALSA (8.9%), and edu-
cation in the Framingham Heart Study (3.3%). As these figures were small, participants with
missing data were simply omitted from regression analyses in which the relevant missing vari-
able was included.
For the Rotterdam Study, the exact date of dementia diagnosis was used if available; other-
wise, the midpoint of the interval between visits was used as the onset time of MCI or dementia
at a study visit (conducted at 4-y intervals) for both cumulative incidence estimates and sub-
distribution hazard regression. In addition, as a sensitivity analysis, we repeated our survival
curves and regression models treating the onset of MCI or dementia as interval censored in
addition to adjusting for competing risk, using the “MIICD” package in R software to estimate
the cumulative incidence, and results were extremely similar except for somewhat larger confi-
dence intervals.
Unlike in the stratified analyses, in the regression analyses, each participant was used only
once. Typically, the baseline visit for the regression analyses was the first visit within the eligi-
ble age window of 60–75 y. For the Framingham Heart Study, MMSE was not available at visits
prior to 1981 (as described above). Thus, for the regression analyses, we reset the baseline visit
as the first visit at which MMSE was available. This had the additional benefit of increasing the
range of baseline ages within the cohort.
Meta-analyses were conducted for the 5-y cumulative incidence estimates for all four
cohorts and then for only the three population-based cohorts. Meta-analyses could not be con-
ducted for the lifetime estimates because they were computed for only two cohorts. As there
was considerable heterogeneity among the studies, a random-effects meta-analysis based on
the DerSimonian–Laird method [53] was used. This analysis was performed using the “meta-
for” package in R software.
Because the primary goal was estimating cumulative incidence and understanding differ-
ences across cohorts and individuals rather than hypothesis testing, these analyses are reported
with confidence intervals rather than statistical significance, and no adjustments are made for
multiple comparisons.
The study was planned in summer of 2014 and conducted through fall of 2016. The original
analysis plan, developed in the initial months of the study, specified using multiple cohort
studies, including NACC as well as three population-based cohorts; stratified analyses in the
three age and APOE-e4 dose groups; and regression models including demographic factors,
cardiovascular risk, and baseline cognitive performance or symptoms, with survival models
accounting for competing risk of death. The idea was that the stratified curves would provide
general estimates, and the regression models more individualized estimates (and in any event
insight into anticipated differences across cohorts). As noted above, after initial exploration,
we decided to use specifically subdistribution hazard regression rather than cause-specific haz-
ard regression models because these offer greater interpretability in the context of risk predic-
tion. In preparation for our first presentation of the findings to the Generation Study team in
April 2015, we also decided to make a table of estimated 5-y cumulative incidence to allow eas-
ier comparison across the studies. After this initial meeting, we also added the lifetime risk esti-
mate, which we thought would be informative for potential participants. We performed the
initial regression models separately by cohort in order to get an idea of how best to present the
data given somewhat different variables available in each cohort, and then settled on a final
analysis plan in spring 2016 that included univariable and two nested models as consistent as
APOE and risk of mild cognitive impairment or dementia for prevention trials
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possible across the four cohorts. The NACC dataset was acquired in summer 2014 (the June
2014 data freeze) and then updated in summer 2016 (the March 2016 data freeze). The SALSA
dataset was acquired in fall 2014, and the Framingham Heart Study dataset in spring 2015.
Rotterdam Study analyses were conducted by Rotterdam Study investigators (F. J. W. and M.
A. I.) beginning in spring 2015, in close collaboration with the rest of the group and sharing R
code used with the other cohorts to ensure consistency.
Results
Composition of the cohorts
Table 1 presents the composition of the four cohorts. The cohorts differed considerably in size
and duration of follow-up, with SALSA much smaller than the other cohorts, and long-term
follow-up available only in the Framingham Heart Study and Rotterdam Study. Other substan-
tial differences were seen in educational attainment, with mean years ranging from less than 8
y in SALSA to nearly 16 y in NACC, and sex, with 33.6% men in NACC compared to 42%–
45% in the three population-based cohorts. The four cohorts also differed markedly in APOE-
e4 allele frequency, ranging from 7.5% in SALSA to 17.8% in NACC. NACC also had a 58.3%
fraction with a family history of dementia, compared to 18.6% in the Rotterdam Study, the
only other site that assessed it.
Stratified cumulative incidence estimates
Fig 1 shows the cumulative incidence of MCI/dementia stratified by baseline age group and
APOE-e4 dose; Fig 2 shows the corresponding curves for dementia alone. These figures show
8.5 y of follow-up for all four cohorts on the same scale, to facilitate comparison. Figs 3 and 4
show lifetime (to age 80–85 y) cumulative incidence curves for MCI/dementia and dementia
alone for the two longer-term cohorts.
Table 2 shows the 5-y cumulative incidence of MCI/dementia for all four cohorts, and
Table 3 the lifetime (to age 80–85 y) cumulative incidence across the two longer-term cohorts;
Tables 4 and 5 show the corresponding data for dementia alone.
Overall, within each cohort, risk of MCI/dementia increased with increasing age and
APOE-e4 dose. However, absolute risks differed substantially across the cohorts, particularly
between NACC and the population-based cohorts. Especially for the MCI/dementia outcome,
the NACC cohort typically had higher risk for any genotype at any age. Differences among the
population-based cohorts were smaller, particularly for longer-term follow-up and the demen-
tia outcome.
Five-year cumulative incidence of MCI/dementia was low in the youngest age stratum, par-
ticularly in the cohort studies, although somewhat higher for APOE-e4-positive individuals,
especially homozygote individuals (23% in NACC and 5%–6% in Framingham and Rotter-
dam). Five-year incidence of MCI/dementia was higher in the highest age stratum, particularly
among APOE-e4/e4 homozygote individuals (38% in NACC and 18%–23% in Framingham
and Rotterdam). Five-year incidence of dementia alone was negligible at younger ages, even in
APOE-e4/e4 homozygote individuals, but rose among older individuals, particularly among
those with APOE-e4/e4 (12% in NACC and 7%–12% in Framingham and Rotterdam). The
meta-analyses of the 5-y cumulative incidence estimates for the MCI/dementia outcome
(Table 2) showed consistent increases in incidence by gene dose within age strata and by age
stratum within gene dose, and were higher when the NACC estimates were included. These
pooled estimates ranged from a low of 1.46% for individuals aged 60–64 y with no copies of
APOE-e4 in just the population-based cohorts to a high of 26.70% for individuals aged 70–75 y
with two copies of APOE-e4/e4 in all four cohorts.
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Estimated only for the Rotterdam Study and the Framingham Heart Study, lifetime inci-
dence, whether for MCI/dementia or for dementia alone, was consistent in the two cohorts (it
was also consistent across age strata, but it should be noted that the strata are not independent
and that older age strata included individuals who survived and did not experience the out-
come in earlier strata). Lifetime incidence rose consistently with APOE-e4 dose: for MCI/
Table 1. Demographic and clinical characteristics of participants in our samples from the National Alzheimer’s Coordinating Center, the Rotter-
dam Study, the Framingham Heart Study, and the Sacramento Area Latino Study on Aging.
Characteristic Cohort
NACC (n = 5,073) RS (n = 6,399) FHS (n = 4,078) SALSA (n = 1,294)
Remaining at 5 y of follow-up 1,865 (36.7%) 5,592 (87.4%) 3,911 (95.9%) 976 (75.5%)
Length of follow-up (years) 3.96 (2.97) 12.64 (6.14) 17.59 (9.09) 6.50 (2.52)
MCI or dementia cases 602 (11.9%) 1,301 (20.3%) 826 (20.3%) 111 (8.6%)
Dementia cases 55 (1.1%) 782 (12.2%) 658 (16.1%) 49 (3.8%)
Male sex 1,707 (33.6%) 2,893 (45.2%) 1,762 (43.2%) 538 (41.6%)
Age (years) at baseline visit 68.7 (4.30) 65.4 (4.18)* 62.0 (1.71)* 67.8 (4.42)
Education (years)# 15.79 (2.99) 12.94 (N/A) 13.20 (N/A) 7.72 (5.42)
Education level
Less than high school 140 (2.8%) 728 (11.4%) 622 (15.3%) 835 (64.5%)
High school 720 (14.2%) 2,773 (43.3%) 1,330 (32.6%) 201 (15.5%)
Some college 815 (16.1%) 1,965 (30.7%) 1,004 (24.6%) 126 (9.7%)
College graduation 3,379 (66.6%) 871 (13.6%) 994 (24.4%) 125 (9.7%)
APOE-e4 allele frequency 17.8% 15.0% 11.7% 7.5%
Genotype
e2/e2, e2/e3, e3/e3 3,431 (67.6%) 4,598 (71.9%) 3,166 (77.6%) 1,112 (85.9%)
e2/e4, e3/e4 1,484 (29.3%) 1,645 (25.7%) 845 (20.7%) 171 (13.2%)
e4/e4 158 (3.1%) 156 (2.4%) 67 (1.6%) 11 (0.9%)
Family history of dementia 2,957 (58.3%) 1,191 (18.6%) N/A† N/A†
Cognitive screening test score (MMSE or 3MS)‡ 29.0 (1.3) 28.5 (1.0) 28.8 (1.4) 86.7 (11.2)
Subjective memory concerns 1,262 (24.9%) 2,759 (43.1%) N/A§ N/A§
Vascular risk score$ 1.32 (1.06) 1.82 (0.85) 1.38 (0.94) 2.13 (1.16)
Vascular risk level
Low (0) 1,264 (24.9%) 263 (4.1%) 702 (17.2%) 70 (5.41%)
Moderate (1/2) 3,096 (61.0%) 4,916 (76.8%) 2,923 (71.7%) 737 (57.0%)
High (3/4/5/6) 713 (14.1%) 1,120 (19.1%) 453 (11.1%) 439 (33.9%)
Data are given as n (percent), mean (standard deviation), or percent.
*For the Framingham Study and the Rotterdam Study, this refers to the age in years of the first study visit within the age 60–75-y window included in the
present analyses. In the regression analyses, mean age in the Framingham Heart Study was 65.39 (standard deviation 3.87) because we used the first visit
with available MMSE as the baseline (see text).
#In the Framingham Heart Study and the Rotterdam Study, the education variable was recorded as categories. To facilitate comparisons with other
samples, the mean was estimated by considering less than high school as 10 y, high school as 12 y, some college as 14 y, and college graduate as 16 y.
Education data for the NACC and SALSA cohorts were translated into the categories as follows: <12 y, less than high school; 12 y, high school; 13–15 y,
some college; and16 y, college graduation.
†Family history of dementia was not available in the SALSA and Framingham Heart Study cohorts.
‡MMSE (range [0, 30], with typical dementia cutoff at ~24); for SALSA, the 3MS was used (range [0,100], with typical dementia cutoff at ~77).
§Subjective memory concerns was not available in the SALSA and Framingham cohorts.
$Vascular risk score was calculated based on a count of standard risk factors, see text for details.
3MS, Modified Mini-Mental State Examination; FHS, Framingham Heart Study; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination;
N/A, not available; NACC, National Alzheimer’s Coordinating Center; RS, Rotterdam Study; SALSA, Sacramento Area Latino Study on Aging.
doi:10.1371/journal.pmed.1002254.t001
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dementia (Table 3), it ranged from 11.94%–15.57% for those with no copies of APOE-e4 to
37.47%–46.66% for APOE-e4/e4 homozygote individuals; for dementia alone (Table 5), it
ranged from 5.26%–6.83% for no copies to 30.76%–40.26 for homozygote individuals.
Subdistribution hazard regression analyses
Results of the subdistribution hazard regression analysis are presented in S1 Appendix Tables
A and B (univariable analyses), S1 Appendix Tables C and D (multivariable analyses modeling
APOE-e4 dose and demographics), and S1 Appendix Tables E and F (additionally including
family history of dementia and cognitive variables). Overall, the regression results were fairly
consistent across the four cohorts, even in the small SALSA cohort, and considerably more
consistent than the cumulative incidence results.
The univariable results (S1 Appendix Table A for MCI/dementia and S1 Appendix Table B
for dementia) were fairly consistent across the two outcomes (although for some variables in
some cohorts the hazard ratios [HRs] were somewhat higher for dementia alone), so we pro-
vide details in the text for the MCI/dementia outcome only. There was substantially higher
risk of MCI/dementia with increasing age (HR 1.08–1.16 per year of age), increasing APOE-e4
dose (for one copy, HR 1.51–2.23; for two copies, HR 2.63–3.57), and lower education (HR
1.41–1.86 for less than high school compared to high school). Family history of dementia also
had a nominally significant effect in both cohorts in which it was measured (HR 1.16–1.27).
On the other hand, male sex, which was protective in the population-based cohorts (although
only nominally significantly so in the Rotterdam cohort, HR 0.83–0.90), carried risk in NACC
(HR 1.36). Subjective memory concerns carried risk in both cohorts that assessed them (HR
1.71–2.62). Higher standardized baseline cognitive screening test score (MMSE or 3MS) was
consistently protective across all cohorts for both outcomes (HR 0.58–0.80 per standard devia-
tion above the mean), except for the MCI/dementia outcome in the Rotterdam cohort. Vascu-
lar risk score had a variable and generally nonsignificant effect across all four cohorts.
The simple multivariable models including APOE and demographic factors (S1 Appendix
Table C for MCI/dementia and S1 Appendix Table D for dementia alone) did not appreciably
change the results for age and APOE-e4 dose, although there was some attenuation of associa-
tions for sex and education. In the more complex model (S1 Appendix Tables E and F), again
the picture was similar, with attenuation for sex and education. It is noteworthy that standard-
ized cognitive screening test score and subjective memory concerns (where available) generally
showed substantial, nominally significant hazard ratios, even controlling for education, and
that (where available) family history of dementia, even when controlling for APOE-e4 dose,
also had an impact.
Discussion
Overall findings
Of 16,844 participants included from all four cohorts, 392 (2.3%) had the APOE-e4/e4 geno-
type, highlighting its low prevalence. Nonetheless, the expected age- and APOE-e4-dose-
related increases in cumulative incidence and relative hazard in the regression models are
readily apparent, even to some extent in the very small SALSA cohort. However, the striking
differences in estimated cumulative incidence, particularly for the MCI/dementia outcome,
Fig 1. Cumulative incidence curves, adjusting for competing risk of mortality, for mild cognitive impairment or
dementia by baseline age and APOE-e4 dose. Note that the strata shown are not independent for the Rotterdam and
Framingham cohorts (see text). MCI, mild cognitive impairment; NACC, National Alzheimer’s Coordinating Center; RS,
Rotterdam Study; SALSA, Sacramento Area Latino Study on Aging.
doi:10.1371/journal.pmed.1002254.g001
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between the population-based cohort studies and the highly ascertained NACC cohort (see
below) suggest that overall APOE-e4-associated incidence is somewhat lower than the modeled
findings previously available in the literature. Comparing 5-y cumulative incidence from the
meta-analyses of the three population-based cohorts to that from NACC, in the youngest age
stratum, cumulative incidence ranged across the three APOE-e4 doses from 1.46% to 5.60% in
the population-based cohorts versus 7.94% to 23.06% in NACC, and in the oldest age stratum
from 5.71% to 20.58% in the population-based cohorts versus 15.16% to 38.34% in NACC.
Similarly, viewing the cumulative incidence for APOE-e4/e4 genotype across the three age
strata, cumulative incidence ranged from 5.60% to 20.58% in the three population-based
cohorts versus from 23.06% to 38.34% in NACC. The NACC findings were largely similar to
those of the prospective analyses of Bonham et al. [24] in the same cohort, although Bonham
et al. [24] focused on the relative risk of APOE-e4 across different age ranges, used different
age categories (unrelated to the Generation Study), and did not incorporate several important
Fig 2. Cumulative incidence curves, adjusting for competing risk of mortality, for dementia by baseline age and
APOE-e4 dose. Note that the strata shown are not independent for the Rotterdam and Framingham cohorts (see text). NACC,
National Alzheimer’s Coordinating Center; RS, Rotterdam Study; SALSA, Sacramento Area Latino Study on Aging.
doi:10.1371/journal.pmed.1002254.g002
Fig 3. Lifetime (to age 80–85 y) cumulative incidence curves, adjusting for competing risk of mortality, for mild cognitive impairment or
dementia by baseline age and APOE-e4 dose. Note that the strata shown are not independent (see text). MCI, mild cognitive impairment.
doi:10.1371/journal.pmed.1002254.g003
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variables in the models (i.e., family history, subjective memory concerns, and baseline cognitive
performance). Moreover, the authors did not perform their analyses in a competing risk frame-
work, which is vital to avoid overestimation of cumulative incidences in aging populations [54].
Differences in cumulative incidence estimates across the sites
Variability related to ascertainment and assessment methods has been reported previously for
MCI and dementia prevalence [55,56]. Such variability is not unique to MCI and dementia,
but can occur in a variety of settings, and is a particular problem for common disorders like
MCI in which a subtle gradation from the normal makes rates especially sensitive to threshold-
ing (e.g., attention deficit hyperactivity disorder, major depression, osteoarthritis).
Overall, as might be expected, absolute risk is more vulnerable to methodological differ-
ences than relative risk, especially over shorter time intervals and for the MCI/dementia out-
come rather than the dementia alone outcome. This is underscored by the generally similar
relative hazards across the regression analyses. These regression findings also contribute to an
understanding of the variation across the cohorts.
Among the three population-based cohort studies, there are known and unknown differ-
ences in race and ethnicity, education, and screening and assessment methods. Nonetheless,
Fig 4. Lifetime (to age 80–85 y) cumulative incidence curves, adjusting for competing risk of mortality, for dementia by baseline age and
APOE-e4 dose. Note that the strata shown are not independent (see text).
doi:10.1371/journal.pmed.1002254.g004
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these three cohorts were generally similar—within expected sampling variation—in their esti-
mates of cumulative incidence for most age and APOE strata. The difference between the pop-
ulation-based cohort studies and NACC, on the other hand, is striking. The NACC cohort is
a volunteer cohort, and as such would not be expected to represent the general population
(although it may be representative of potential trial participants, as discussed below). Individuals
join this cohort for a variety of reasons, but concerns about family history and their own mem-
ory are likely to play a role. This probably contributes to the relatively high APOE-e4 allele fre-
quency and reported family history of dementia in this cohort seen in Table 1, although some of
the difference in family history likely represents measurement issues (see below). Since family
history increases risk beyond the APOE-e4 effect in these and other data [57,58], the high fre-
quency of positive family history likely contributed to some of the observed differences in inci-
dence. Another potential source of difference is the very high level of educational attainment
within the NACC cohort. While higher education is associated with lower risk of dementia over-
all, more educated individuals with memory concerns actually have higher risk of developing
dementia than their counterparts with less education [59], and this may be particularly true for
the highly educated individuals who form a substantial fraction of the NACC cohort. Another
issue is the high proportion of women in the NACC cohort; differences in the reasons that men
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and women volunteer for this cohort may underlie the increased risk of MCI and dementia for
men observed in the regression analyses. Last, the NACC samples serve a variety of needs across
the different Alzheimer’s Disease Centers in the United States; there is often substantial dropout
and variable effort to retain participants, and decisions by participants and center staff are not
likely to be random with respect to cognitive and other variables. While the population-based
cohort studies also have some dropout, systematic ongoing efforts to retain participants and
continuous surveillance even for those who do not attend study visits guarantee low attrition.
Beyond these differences in ascertainment, demographics and other attributes, and follow-
up, there are differences in assessment between NACC and the three population-based cohorts
that should be noted. The population-based cohorts evaluate cognition with a screening proce-
dure typically followed by more formal clinical evaluation of participants who screen positive.
While direct clinical evaluation of all participants at each NACC site is a strength, there are
procedural differences across sites, quality control is limited, and the reliability of NACC diag-
nosis is not well established. In addition, the high educational level of NACC participants is
not well captured by available norms, and a subset of individuals may have declined substan-
tially but nonetheless may be viewed as cognitively unimpaired. This is a particular concern
because within any group of normal individuals, those who are already declining are more
likely to continue to do so [60–62]. Thus, baseline cognitive symptoms and preexisting sub-
threshold decline, both likely to be more frequent in the highly educated NACC cohort, have a
substantial impact on short-term onset of MCI and even dementia. This phenomenon may
underlie the higher risk of cognitive decline noted earlier for more versus less educated indi-
viduals among those with subjective cognitive concerns [59].
Of course, it is likely that there is some insensitivity to MCI and even dementia in the popu-
lation-based cohort studies as well as differential loss to follow-up, but on balance the volun-
teer nature of the NACC cohort, the limited quality control across the NACC sites, and the
consistency of the population-based cohort findings tend to favor the lower cumulative inci-
dence found in the population-based cohorts.
Table 3. Lifetime (to age 80–85 y) cumulative incidence of mild cognitive impairment/dementia by baseline age and APOE-e4 dose.
Age (years) and APOE Cohort
RS* FHS*
n Lifetime cumulative incidence, percent (95% CI) n Lifetime cumulative incidence, percent (95% CI)
Age 60–64
0 e4 2,625 14.05 (12.50, 15.78) 2,955 11.94 (10.56, 13.49)
1 e4 928 25.37 (21.96, 29.21) 795 22.07 (18.69, 25.94)
2 e4 102 37.47 (25.11, 53.34) 62 45.15 (31.32, 61.70)
Age 65–69
0 e4 2,492 14.23 (12.83, 15.76) 2,430 12.22 (10.80, 13.81)
1 e4 906 25.44 (22.50, 28.69) 646 23.33 (19.76, 27.44)
2 e4 77 38.09 (27.25, 51.46) 44 46.66 (31.56, 64.65)
Age 70–75
0 e4 2,212 15.57 (14.11, 17.16) 1,888 11.94 (10.43, 13.64)
1 e4 739 26.14 (23.10, 29.51) 464 21.35 (17.58, 25.80)
2 e4 59 38.02 (26.76, 52.04) 32 37.55 (22.42, 58.23)
For age 60–64 y, lifetime cumulative incidence is estimated as 20-y cumulative incidence. For age 65–69 y, lifetime cumulative incidence is estimated as
15-y cumulative incidence. For age 70–75 y, lifetime cumulative incidence is estimated as 10-y cumulative incidence.
*Individuals could contribute to multiple baseline age strata.
FHS, Framingham Heart Study; RS, Rotterdam Study.
doi:10.1371/journal.pmed.1002254.t003
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Comparison to modeled estimates from the literature
One could argue that previously available modeled estimates for APOE-e4-associated absolute
risk for dementia [17,19] are high (50%–67%), and thus favor the NACC estimates instead.
Our estimates of lifetime risk for dementia for APOE-e4/e4 individuals from the Framingham
Heart Study and the Rotterdam Study are in the 31%–40% range. While we did not estimate
lifetime cumulative incidence for NACC given the short mean duration of follow-up, it would
be expected to be considerably higher than the 5-y estimates—in the oldest APOE-e4/e4 homo-
zygote individuals, 38.3% for MCI or dementia and 12.4% for dementia alone. However, there
are some biases in the modeled estimates that overall are more likely to yield over- rather than
underestimates of risk.
For the Cupples et al. estimates used in the REVEAL study [17], risk curves for incidence
were derived from relatives and spouses in a family sample ascertained from a clinical popula-
tion [18]; these incidence rates could be expected to be higher than those in the general popu-
lation. In addition, the relative risks by sex, age, and genotype were applied from a large meta-
analysis done primarily in clinically ascertained, younger-onset families [14], again yielding
higher estimates [14,63]. In addition, the competing risk of death was not addressed in the
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cumulative incidence estimates, which also would tend to bias estimates upward. Moreover,
the Cupples model does not account for the correlation among observations in the family sam-
ple used for incidence, which again might lead to bias [64].
For the Genin et al. estimates used by 23andMe [19], relative risks from a European GWAS
[21] were applied to incidence estimates from the Rochester [22] and PAQUID [23] cohorts.
The relative risk estimates come from cases and controls, with younger cases (with a greater
APOE-e4 effect) overrepresented. In addition, these models assumed that the controls in
GWAS samples were representative of the overall population. This likely does not hold with a
very common disease like dementia (which occurs in over 10% of those over 65 y and 35% or
more of those over 85 y [1]) because at higher ages those without dementia are fundamentally
a selected sample. This also would tend to bias the estimates upward.
Insights from the regression models
Overall, the substantial effects of age and APOE-e4 dose were consistent across the univariable
and basic and more complex multivariable models, persisting even when other demographic
factors as well as cognitive variables and family history were taken into account. Education
also exhibited a dose response, but behaved less consistently, as much illustrating as illuminat-
ing the profound differences in education across these four cohorts.
The effect of sex is even less consistent, perhaps reflecting ascertainment and cultural differ-
ences across disparate cohorts; findings in the literature are also inconsistent [23,65,66]. Some
studies suggest also that APOE-e4 behaves differently by sex, with a greater effect in women
[67,68]. If we had had sufficient sample size, we would also have stratified our risk estimates
on sex or considered including an interaction term in our regression models. However, in the
population-based cohorts for the MCI/dementia outcome, there was strong attenuation of the
effect estimates of sex when adjusting for educational attainment, suggesting that lack of edu-
cational attainment in women of older birth cohorts may partly explain the difference.
Table 5. Lifetime (to age 80–85 y) cumulative incidence of dementia by baseline age and APOE-e4 dose.
Age (years) and APOE Cohort
RS* FHS*
n “Lifetime” cumulative incidence, percent (95% CI) n “Lifetime” cumulative incidence, percent (95% CI)
Age 60–64
0 e4 2,625 6.83 (5.59, 8.33) 2,955 6.22 (5.23, 7.40)
1 e4 928 17.18 (14.06, 20.90) 795 15.93 (12.98, 19.47)
2 e4 102 34.69 (22.75, 50.49) 62 38.49 (25.50, 55.17)
Age 65–69
0 e4 2,492 5.26 (4.37, 6.34) 2,430 6.59 (5.53, 7.84)
1 e4 906 15.36 (12.93, 18.20) 646 16.22 (13.16, 19.92)
2 e4 77 30.76 (20.74, 44.09) 44 40.26 (25.75, 59.00)
Age 70–75
0 e4 2,212 5.76 (4.86, 6.83) 1,888 5.65 (4.61, 6.91)
1 e4 739 14.77 (12.38, 17.58) 464 13.94 (10.82, 17.86)
2 e4 59 33.30 (22.54, 47.37) 32 35.17 (20.32, 56.27)
For age 60–64 y, lifetime cumulative incidence is estimated as 20-y cumulative incidence. For age 65–69 y, lifetime cumulative incidence is estimated as
15-y cumulative incidence. For age 70–75 y, lifetime cumulative incidence is estimated as 10-y cumulative incidence.
*Individuals could contribute to multiple baseline age strata.
FHS, Framingham Heart Study; RS, Rotterdam Study.
doi:10.1371/journal.pmed.1002254.t005
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However, for dementia only in the same cohorts, a nominally statistically significant higher
risk in women persisted even after adjustment for demographics and other risk indicators.
Conversely, in NACC, there was a higher risk in men, which we believe is likely related to
ascertainment differences by sex in this convenience sample, as noted above. Overall, potential
sex differences deserve particular focus in future studies given the complex relationships
among sex, education, vascular risk factors, birth cohort, longevity, and genetics.
Also of potential relevance, both to potential participants wishing to understand their abso-
lute risk and to investigators designing clinical trials, both cognitive performance and subjec-
tive memory concerns were associated with an increased hazard of MCI or dementia. All in
all, these associations suggest that relatively simple individual characteristics might be used to
further refine individual risk stratification beyond age and APOE genotype.
Implications for study design and genetic counseling
For the purposes of the Generation Study and other prevention trials, absolute cumulative
incidence, both during the 5-y duration of the trial and over the remaining lifetime, is critical,
but the differences across these cohort studies make it difficult to offer precise estimates, even
with meta-analyses. In an ideal world, estimates would be tailored to the population entering
the trial or, better still, the specific individuals, and would take into account not only explicit
inclusion criteria but also any other measureable or predictable characteristics that might
predict willingness to volunteer. A review of the first registrants on the GeneMatch registry,
which serves as the primary US recruiting site for the Generation Study APOE-e4/e4 trial,
shows that registrants differ from the general population beyond the explicit entry criteria.
The population of 13,704 registrants enrolled thus far is relatively young (mean age 62.7 y,
standard deviation 5.2) and women are overrepresented (80%). Among the 4,978 registrants
who were asked about race/ethnicity, 92% are white. The frequency of the APOE-e4/e4 geno-
type among registrants is higher than in the general population, at 4.47%, and the APOE-e4
allele frequency is 20.4%; among the 3,456 registrants asked about whether they had a family
history of dementia or Alzheimer disease, 70.1% said yes. While education was not measured,
the high percent of females and individuals with a significant family history (and the high
APOE-e4 frequency) suggests a population that may be more like NACC. However, data on
education, cognitive performance, and subjective memory concerns are not available. More-
over, over time, if there are broader recruiting efforts in order to reach the target sample size,
volunteers could gradually become more reflective of the general population, and lower risks
might be expected.
In the genetic counseling setting, any risk information would need to give a broad range of
estimates to reflect uncertainty within cohorts and variation across cohorts. Because risk for
disease is ongoing, and the lifetime risks were more stable than the 5-y risks in our analyses,
we thought the lifetime risks were more informative for genetic disclosure. However, such
risks may be less salient to some of those considering enrollment in trials at younger ages. The
Generation Study elected to disclose the following “lifetime” risks of MCI or dementia to its
potential participants: 30%–55% for individuals with APOE-e4/e4; 20%–25% for individuals
with APOE-e3/e4 and -e2/e4 (with a note that risk might be lower for those with APOE-e2/e4);
and 10%–15% for individuals with APOE-e3/e3, -e3/e2, and -e2/e2 (with a note that risk might
be lower for those with APOE-e2/e3 and -e2/e2). These values are consistent with our findings,
but use round numbers for intelligibility, and broader ranges to reflect statistical and other
sources of uncertainty. The regression models are insufficiently precise for “personalized med-
icine” incidence estimates based on sex, education, or other factors, but they do allow for quali-
tative adjustments to overall stratified risk estimates. Relative risks by APOE genotype or
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APOE-e4 dose have limited relevance in the setting of the prevention trial, but may provide
context. If these are provided, risk should be compared to the general population (based on a
weighted average across the three possible APOE-e4 doses rather than the typical “no APOE-
e4” base category used in regression models), which would more fairly allow a participant to
put his or her own risk in the context of friends and acquaintances of unknown genotype. On
the basis of our regression findings (S1 Appendix Table E), for APOE-e4/e4 homozygotes, the
adjusted relative risk for MCI/dementia is 2.7 for NACC, 3.4 for the Framingham Heart Study,
and 2.4 for the Rotterdam Study, so disclosing a relative risk of about 3-fold compared to the
general population would make sense. Use of pictographs as a visual aid for risk communica-
tion could be useful, given their ability to visually represent both absolute and relative risk
information simultaneously [69]. In addition, there is a robust literature on genetic risk com-
munication that can inform best practices in cases where APOE information is disclosed to
asymptomatic individuals [70].
Limitations
One major limitation of this study is that APOE-e4/e4 samples are small despite the large size
of the initial cohorts, particularly for SALSA. This limits the stability of stratified cumulative
incidence estimates (only partially addressed by the meta-analyses) as well as regression coeffi-
cients for APOE-e4 dose. This issue is further complicated by missing data (likely not missing
at random) and likely differential dropout. Second, while the four cohorts are heterogeneous
in sex distribution and education, there is little ethnic and racial diversity, so the findings are
less relevant to participants of non-European background. Third, variations in the definitions
of the exposure and outcome variables may hamper comparisons among cohorts. As noted
above, each cohort uses different criteria to define unimpaired at baseline, and to screen,
assess, and diagnose new onset cases. Different psychometric tests are applied, and even the
same test performs differently across different groups; education- and/or age-adjusted norms
can compensate for this, but may introduce other problems in interpretation. Other variation
may come from differences in definitions (e.g., family history is based on a single question
about parents only in the Rotterdam Study versus a detailed set of questions about each parent
and sibling in NACC) or in how information is acquired (being positive for memory concerns
is based on a yes answer to any one of three questionnaire items in the Rotterdam Study versus
an overall clinical impression about the participant’s attitude in NACC). Moreover, some vari-
ables, notably level of education, may be defined similarly but have different meanings within
different cultural contexts. Nevertheless, as we have shown, relative risk estimates are consis-
tent despite this variation. Fourth, regression models for MCI or dementia are limited because
of confounding and omitted predictors, and are complicated by multicollinearity of exposure
and outcome variables that represents confounding, effect modification, and true signal.
Conclusion
Prospective cohort studies can be used to inform study design, power, and informed consent
in clinical trials among cognitively unimpaired individuals. While trial designers and partici-
pants may be most interested in absolute risk over relatively short intervals, absolute risk is less
robustly estimated than relative risk, and short-term risk less robustly estimated (and more
sensitive to the definition and operationalization of cognitively unimpaired at baseline) than
long-term risk. Estimation that serves informed consent and optimal trial design will require
matching the cohort used to estimate risk as closely as possible to trial participants.
Overall, the estimates for APOE-associated risk of MCI or dementia were lower in our
study than previously reported, and there is reason to believe that the risk estimates obtained
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in the population-based cohorts more accurately reflect the general population than those
obtained in NACC. However, these lower risks may less accurately match the likely trial popu-
lation. In general, such estimates are also sensitive to variation in sampling, assessment, and
modeling. Rigorous attention to sampling, assessment, and statistical methods is critical to
developing the best possible answers for clinical trial design.
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